JUVE Patent
Back to all Experts
Firm Profile
About Dr. Marco Stief, LL.M.
Marco Stief is a highly experienced lawyer, skilled in handling national and international patent infringement cases, border seizure proceedings and conflicts arising from technology-related contracts. He advises companies in the areas of technical IP rights, technology transfers and also on a wide variety of contractual matters. He acts in an advisory capacity on questions relating to design rights, competition law, employee inventions and trade secrets.
Marco has headed Maiwald’s legal department since 2017. He lectures in intellectual property rights at the University of Dresden and is associate lecturer in patent and international contract law at the University of Marburg.
Dr. Marco Stief, LL.M.
Maiwald Intellectual Property
Elisenhof, Elisenstraße 3
80335 Munich
Germany
+49 (0)89 747 266 0
Stief@maiwald.eu
1 Specialism
- Pharmaceuticals
Awards
- Listed in IAM Strategy 300 as one of the world's leading IP strategists 2021, 2022, 2023
- Awarded in MIP "IP Stars" 2017, 2021, 2022, 2023, 2024
- Listed in Handelsblatt 2021 and 2024 as lawyer of the year in the category healthcare law
- Listed in Handelsblatt 2021 as best lawyer for Healthcare in Bavaria
- Listed as best lawyer in Handelsblatt 2021 in the categories Biotechnology Law, Healthcare Law and Pharmaceutical Law
- Listed in IAM Strategy 300 Global Leaders 2021, 2022, 2023, 2024, 2025
- Listed in JUVE Patent as "Advisor in patent litigation" 2020/2021
- Listed in the WirtschaftsWoche "Die renomiertesten Patentrechtsanwälte" 2020, 2021, 2022, 2024
- Named in JUVE Top 8 German patent litigators under 50 2019, 2020, 2021
- Named in Who’s Who Legal 2019 and 2020 as one of the six most highly regarded German patent litigators, recognized by Who’s Who Legal as Thought Leader (Germany) in Patent Law (2021), Global Leader IP-Patents (2021), Life Sciences Patent Litigation (2022), National Leader Germany-Patents (2022, 2023), Thought Leader Germany-Patents (2022), Global Leader IP-Patents (2022), Listed as One of the world’s leading practitioners in the Who's Who Legal: IP 2023 report, recommended in the Germany ranking (2024)
- Listed in the WirtschaftsWoche "Die besten Anwälte für Patentrecht und Urheberrecht" 2019
- Recommended in Expert Guides - Life Sciences for IP and Regulatory 2019
- Recommended in Handelsblatt | Best Lawyers "Germany's Best Lawyers" 2019, 2020, 2021, 2022, 2023, 2024
- Recommended in Legal 500 EMEA 2019, 2020, 2021, 2022, 2023, 2024
- Named in JUVE Top 12 German patent litigators under 50 2018/2019
- Named in Chambers Europe 2018
- Recommended in Legal 500 Deutschland 2017, 2019, 2020, 2021, 2022, 2023, 2024
- Winner of the “Client Choice Award 2015/2016 for Patent Law”
- Recommended in WirtschaftsWoche 2015
- For many years listed in IAM Patent 1000 „World’s Leading IP Litigators“
- For many years listed in IAM Strategy 300 „World’s Leading IP Strategists“
- Recommended in the Leaders League Rankings Germany 2022 in the category Patent Litigation
- For many years “frequently recommended lawyer” in the JUVE Handbook of Commercial Law Firms
- Listed as “Thought Leader IP” and “Recommended” in Who's who Legal IP, 2024
- Listed as "Excellent" in the Patent Litigation category and as "Highly recommended" in the Healthcare & Pharmaceuticals category in the Leaders League Rankings Germany 2024
Sponsored Content
Publications
- Germany permits service of claims on Chinese defendants by publication, Managing IP 2025
- Patentstrategien und deren Auswirkungen auf den Wettbewerb im Bereich der Pharmazeutischen Industrie, PharmR 3/2025
- Der Begriff des Wirkstoffs i.S.d. Art. 1 lit. b SPC-VO, GRUR Patent – Patentrecht in der Praxis, 2025
- Verletzung von Pharmapatenten, Rechtsfolgen und Passivlegitimation, PharmR 12/2024
- Interview IAM Strategy 300 Global Leaders, 2024
- Klinische Studien als neuheitsschädliche Vorbenutzung im Sinne von § 3 PatG, PharmR 8/2024 (German only)
- Die Marktexklusivität als absolutes Recht (Teil II), GRUR 16/2024
- Wündisch/Zirkel, F&E-Verträge, Handbuch für Wissenschaft und Praxis, 2024 (German only) Chapter on the Unified Patent Court and Unitary Patent and on the special features of research and development in the pharmaceutical and life sciences sector
- Praktische Erfahrung mit der Grenzbeschlagnahme nach VO (EG) Nr. 1383/2003, in: Festschrift für Ulf Doepner, Reese/Hufnagel/Lensing-Kramer (eds.), C.H.BECK, 2008 (together with Peter Chrocziel)
- Neurim and SPCs: Justice for indication inventions, Managing Intellectual Property, 12/2012
- Handbuch des Patentrechts, Haedicke/Timmann (eds.), C.H.BECK, 2012 (together with Johannes W. Bukow et al.)
- Questions submitted on scope of Bolar provision, Managing Intellectual Property, 02/2014
- Patent Law – A Handbook on European and German Patent Law, Haedicke/Timmann (eds.), C.H.BECK, 2014 (together with Dirk Bühler et al.)
- Revised TTBER and Guidelines, Managing Intellectual Property, 01/2015
- Safe harbors in Europe: an update on the research and Bolar exemptions to patent infringement, Nature Biotechnology, 07/2015 (together with András Kupecz et al.)
- BGH “Filmscanner” judgment reviewed, Managing Intellectual Property, 09/2016
- CJEU requirements in FRAND cases, Managing Intellectual Property, 10/2016
- Supplementary Protection Certificates (SPC), C.H.BECK, 2016 (jointly published with Dirk Bühler)
- Recent developments in German jurisprudence following ECJ “Huawei Technologies / ZTE“, Managing Intellectual Property, 02/2017
- Designrechtler, Karriereführer, 03/2017
- Process patents and the partial outsourcing of individual procedural steps into patent-free foreign countries – opportunity or risk?, Expert Guides, 03/2017 (together with Katja Bolender)
- Vertragshandbuch Pharma und Life Sciences, C.H.BECK, 2nd edition, 2019 (jointly published with Boris Bromm)
- Pharmaceutical, Biological and Chemical Patents, C.H.BECK, 2019 (jointly published with Maximilian Haedicke and Dirk Bühler)
- Zwischen Pregabalin und Fulvestrant. Ein Vergleich des deutschen und englischen Hanftungsregimes bei Swiss-type-claims anlässlich aktueller Rechtsprechung, GRUR, 03/2019 (together with Ulrike Zorr)
- New liabilty for second medical use, Managing Intellectual Property, 03/2019 (together with Ulrike Zorr)
- Pregabalin and Fulvestrant - a comparison of German and English liability regimes for Swiss-type claims in light of current case law, Journal of Intellectual Property Law & Practice, 06/2019 (together with Ulrike Zorr)
- Legal Problems of the Supplementary Protection Certificate for Medicinal Products. Using the example of medical indications, excipients and combinations of active ingredients, Carl Heymanns Verlag, 1st edition, 2020
- Handbuch des Patentrechts, Haedicke/Timmann (eds.), C.H.BECK, 2nd edition 2020 (together with Johannes W. Bukow et al.)
- Vertragshandbuch Pharma and Life Sciences
- Do the experimental use and bolar exemptions also apply in contributory patent infringement cases? Journal of Intellectual Property Law and Practice, 2022
- EU-Initiative zu Zwangslizenzen – Chance oder Wettbewerbsnachteil? Arzneimittel & Recht, 2022
- Originator vs Generika – Pharmapatente im Spannungsfeld des einstweiligen Verfügungsverfahrens, PharmR Heft 6/2022
- Haftungsbegrenzungen und Freistellungsvereinbarungen insbesondere in Technologie- und Unternehmenskaufverträgen (M&A), Lizenz- und F&E-Verträgen, 2022
- Vertragliche IP Garantien in Pharmaverträgen, insbesondere M&A, Lizenz und F&E Verträge, 2022
- Do the experimental use and bolar exemptions also apply in contributory patent infringement cases? Journal of Intellectual Property Law and Practice, 2022
- Regulatorische und haftungsrechtliche Herausforderungen für KI-Medizinprodukte, in Roman Grinblat/ Sibylle Scholtz/ Sophy Stock (Hrsg.) Festschrift für Ulrich M. Gassner, Medizinprodukterecht im Wandel (S. 467 ff.), Nomos, 2022
- Originator vs Generika – Pharmapatente im Spannungsfeld des einstweiligen Verfügungsverfahrens, PharmR Heft 6/2022, Heft 8/2022
- Ergänzende Schutzzertifikate – Überblick und Ausblick zur EU-Initiative, Arzneimittel & Recht, 2022
- Einheitspatent und einheitliches Patentgericht – Vorstellung des neuen europaweiten Patent- und Gerichtssystems, PharmaR 10/2022
- Preisanpassungsklauseln bei Verträgen zwischen Unternehmen, Betriebs-Berater 43/2022
- IP Due Diligence und Pharma, |transkript 4-2022 im November – Spezial: “Patente / M&A / Lizenzierung”
- Proportionality defence v compulsory licence: the decision of the Düsseldorf court, Managing IP 2022
- Article No challenge clauses Pay-for-delay agreements, A.I.P.P.I. Japanese Journal Vo.67 No. 3 p.31 2022 (Japanese only)
- Einheitspatent und einheitliches Patentgericht – Konsequenzen für Schutzrechte und Technologieverträge, PharmR 12/2022
- Interview IAM Strategy 300 Global Leaders, 2023
- IP as a means of securing a loan under German law, Managing IP 2023
- Die Reform der Gruppenfreistellungsverordnungen – FuE- und Spezialisierungs-GVO 2023, Wirtschaft und Wettbewerb 01/2023
- Europe’s new Unitary Patent System will affect IP Agreements, Law360 2023
- Der patentrechtliche Verhältnismäßigkeitsgrundsatz im Bereich Arzneimittel und Medizinprodukte, Teil 1, PharmR 2/2023
- No-challenge and pay-for-delay agreements in patent licence and settlement agreements under European competition law, Journal of Intellectual Property Law & Practice, Vol. 18/2, 02/2023, S.135–145
- Die Einführung eines neuen Patentsystems in Europa, Betriebs-Berater 2023, Heft 09
- Louboutin v Amazon: direct liability of online platforms for third-party trademark infringement, MIP 2023
- Pharmaceutical, Biological and Chemical Patents, C.H.BECK – 2023
- Der patentrechtliche Verhältnismäßigkeitsgrundsatz im Bereich Arzneimittel und Medizinprodukte, Teil 2, PharmR 3/2023
- EuGH: Plattformbetreiber haften für Markenrechtsverletzungen durch Drittanbieter – der Fall Louboutin/Amazon, BetriebsBerater 12/2023
- Der texanische “Two-Step”- Umstrittene juristische Strategie zur Begrenzung der Unternehmenshaftung, Arzneimittel & Recht 2/23
- Quo vadis Arzneimittelrecht – ein Überblick zur Überarbeitung der EU-Arzneimittelvorschriften, PharmR 6/2023
- Ersatzansprüche bei ungerechtfertigten einstweiligen Verfügungen im Pharmabereich – Ansprüche des Antragsgegners und geschädigter Dritter, GRUR 13/2023
- Unitary Patent and Unified Patent Court (1) – Implications and recommendations for patent owners, licensees and technology companies, AIPPI, 2023 (Japanes only)
- Unitary Patent and Unified Patent Court (2) – Implications and recommendations for patent owners, licensees and technology companies, AIPPI, 2023 (Japanese only)
- European Commission proposes transferable data exclusivity vouchers to tackle the antimicrobial resistance crisis, Managing IP 2023
- European Unitary Patent Package: Introduction to the New System including Strategic Considerations, (September 2023) 133 Intellectual Property Forum 40
- The springboard doctrine in the context of patent law – part two, Managing IP 2023
- The springboard doctrine in the context of patent law – part one, Managing IP 2023
- Does current legislation provide for adequate compensation in cases of unjustified preliminary injunctions? Originator–generic conflicts in the context of patent infringement proceedings, Journal of Intellectual Property Law & Practice, 12/2023 (Stief/Geller)
- (No) injunctive relief before the actual grant of a patent, GRUR 23/2023
- Rechtshandbuch Chemie-, Pharma- und Life-Science-Patente, C.H. Beck – 2023
- Wettbewerbsrecht im Kontext von F&E- und Linzenzverträgen, PharmR 3/2024
- § 945 ZPO – Ausweitung der Haftung der Originatoren bei später widerrufenem Patent?, GRUR 4/2024 (Stief/Meyer)
- Unitary Patent and Unified Patent Court – the new europe-wide patent and court system, Zhichanli, 2024 (Chinese only)
- Not without my consent – Zu den Grenzen des SPC squatting, GRUR 6/2024
- Wettbewerbsrecht im Kontext von Technologietransfer- und Lizenzverträgen, PharmR 4/2024
- Die Marktexklusivität als absolutes Recht (Teil I), GRUR 11/2024
